Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on AJ Bell following 'strong' Q3

(Sharecast News) - Analysts at Berenberg hiked their target price on online investment platform operator AJ Bell from 420.00p to 490.00p on Tuesday as it praised the group's "strong" Q3 performance. Berenberg said net flows into AJ Bell continued to "remain strong" in Q325, coming in ahead of consensus expectations. Coupled with a strong period for markets, Berenberg noted that this meant AJ Bell's assets under administration had risen by 6% quarter-on-quarter and 15% year-on-year.

The German bank noted that AJ Bell's management highlighted that Q325 was a record quarter for net flows, with the business benefiting from investment in its brand and propositions.

"We increase our forecast EPS by c15% for FY25 and c11% for outer years. This is driven by the strong market performance in Q3, increases to our flow expectations in the D2C channel, and higher transactional-linked revenue given market volatility; partially offset by higher operational, technology and marketing costs," said Berenberg, which reiterated its 'hold' rating on the stock.

Berenberg added that AJ Bell currently trades on a roughly 22x forward price-to-earnings ratio.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.